Literature DB >> 19448841

Targeting sphingosine 1 phosphate receptor type 1 receptors in acute kidney injury.

Mark D Okusa1, Kevin R Lynch.   

Abstract

Sphingosine 1-phosphate analogs have a multitude of effects with the best characterized one being mediated through sphingosine 1-phosphate type 1 receptors (S1P1 receptor). Currently, S1P1 receptor agonists are being developed and tested for human disease. Because of the potent effect of S1P1 agonists to modulate the immune system, these compounds are ideal for blocking immune mechanisms that mediate acute kidney injury (AKI). This disorder continues to remain an important disease that is characterized by high morbidity and mortality. Currently there are no FDA approved drugs for the treatment of AKI. This review summarizes current knowledge on the mechanism of AKI due to ischemia-reperfusion and early studies that target S1P1 receptors for the treatment and prevention of AKI.

Entities:  

Year:  2007        PMID： 19448841      PMCID： PMC2682423          DOI： 10.1016/j.ddmec.2007.07.001

Source DB:  PubMed          Journal:  Drug Discov Today Dis Mech        ISSN： 1740-6765


  65 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

Review 2.  Sphingosine 1-phosphate, a key cell signaling molecule.

Authors:  Sarah Spiegel; Sheldon Milstien
Journal:  J Biol Chem       Date:  2002-05-13       Impact factor: 5.157

3.  Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720.

Authors:  Elzbieta Sawicka; Claudia Zuany-Amorim; Corinne Manlius; Alexandre Trifilieff; Volker Brinkmann; David M Kemeny; Christoph Walker
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

4.  Renal ischemia and reperfusion impair endothelium-dependent vascular relaxation.

Authors:  W Lieberthal; E F Wolf; H G Rennke; C R Valeri; N G Levinsky
Journal:  Am J Physiol       Date:  1989-05

Review 5.  Sphingosine 1-phosphate: a prototype of a new class of second messengers.

Authors:  S Spiegel
Journal:  J Leukoc Biol       Date:  1999-03       Impact factor: 4.962

6.  Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells.

Authors:  Sergey V Brodsky; Tokunori Yamamoto; Tetsuhiro Tada; Byungsoo Kim; Jun Chen; Fumihiko Kajiya; Michael S Goligorsky
Journal:  Am J Physiol Renal Physiol       Date:  2002-06

7.  FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.

Authors:  Shaun M Honig; Shuang Fu; Xia Mao; Adam Yopp; Michael D Gunn; Gwendalyn J Randolph; Jonathan S Bromberg
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

8.  Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells.

Authors:  Jenny H Xie; Naomi Nomura; Sam L Koprak; Elizabeth J Quackenbush; Michael J Forrest; Hugh Rosen
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

9.  The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.

Authors:  Steven W Paugh; Shawn G Payne; Suzanne E Barbour; Sheldon Milstien; Sarah Spiegel
Journal:  FEBS Lett       Date:  2003-11-06       Impact factor: 4.124

10.  Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets.

Authors:  Yohichi Yasunami; Satoshi Kojo; Hiroshi Kitamura; Atsushi Toyofuku; Masayuki Satoh; Masahiko Nakano; Kentaroh Nabeyama; Yoshiichiroh Nakamura; Nobuhide Matsuoka; Seiyo Ikeda; Masao Tanaka; Junko Ono; Naoki Nagata; Osamu Ohara; Masaru Taniguchi
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307
View more
  4 in total

Review 1.  Cellular and Molecular Mechanisms of AKI.

Authors:  Anupam Agarwal; Zheng Dong; Raymond Harris; Patrick Murray; Samir M Parikh; Mitchell H Rosner; John A Kellum; Claudio Ronco
Journal:  J Am Soc Nephrol       Date:  2016-02-09       Impact factor: 10.121

2.  Lysophosphatidic acid increases proximal tubule cell secretion of profibrotic cytokines PDGF-B and CTGF through LPA2- and Gαq-mediated Rho and αvβ6 integrin-dependent activation of TGF-β.

Authors:  Hui Geng; Rongpei Lan; Prajjal K Singha; Annette Gilchrist; Paul H Weinreb; Shelia M Violette; Joel M Weinberg; Pothana Saikumar; Manjeri A Venkatachalam
Journal:  Am J Pathol       Date:  2012-08-10       Impact factor: 4.307

3.  Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury.

Authors:  Sophia M Sears; Tess V Dupre; Parag P Shah; Deanna L Davis; Mark A Doll; Cierra N Sharp; Alexis A Vega; Judit Megyesi; Levi J Beverly; Ashley J Snider; Lina M Obeid; Yusuf A Hannun; Leah J Siskind
Journal:  J Lipid Res       Date:  2022-02-10       Impact factor: 5.922

4.  Sphingosine-1-phosphate acts as a key molecule in the direct mediation of renal fibrosis.

Authors:  Shunji Shiohira; Takumi Yoshida; Hidekazu Sugiura; Miki Nishida; Kosaku Nitta; Ken Tsuchiya
Journal:  Physiol Rep       Date:  2013-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.